NCT07033026 An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
| NCT ID | NCT07033026 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | NGM Biopharmaceuticals, Inc |
| Condition | Colorectal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 136 participants |
| Start Date | 2025-06-25 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 136 participants in total. It began in 2025-06-25 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Eligibility Criteria
Inclusion Criteria: 1. Documented active diagnosis of colorectal cancer. 2. Cachexia defined by Fearon criteria of weight loss. 3. Signed informed consent. Exclusion Criteria: 1. Current active reversible causes of decreased food intake. 2. Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization. 3. Have cachexia caused by other reasons.
Contact & Investigator
NGM Study Director
STUDY DIRECTOR
NGM Biopharmaceuticals, Inc
Frequently Asked Questions
Who can join the NCT07033026 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07033026 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07033026 currently recruiting?
Yes, NCT07033026 is actively recruiting participants. Contact the research team at NGM120CX@ngmbio.com for enrollment information.
Where is the NCT07033026 trial being conducted?
This trial is being conducted at Los Angeles, United States, Los Angeles, United States, Santa Rosa, United States, Margate, United States and 11 additional locations.
Who is sponsoring the NCT07033026 clinical trial?
NCT07033026 is sponsored by NGM Biopharmaceuticals, Inc. The principal investigator is NGM Study Director at NGM Biopharmaceuticals, Inc. The trial plans to enroll 136 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.